uniQure (NASDAQ:QURE) Shares Down 4.8% – Time to Sell?

uniQure (NASDAQ:QURE) was down 4.8% during trading on Tuesday . The company traded as low as $15.08 and last traded at $15.05. Approximately 74,702 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 1,144,552 shares. The stock had previously closed at $15.80.

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of recent research reports. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Stifel Nicolaus increased their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Finally, Mizuho raised their target price on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Performance

The stock’s 50 day moving average price is $12.93 and its 200 day moving average price is $8.74. The company has a market capitalization of $738.65 million, a P/E ratio of -3.06 and a beta of 0.41. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities analysts expect that uniQure will post -3.74 EPS for the current year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the company. American Century Companies Inc. increased its holdings in uniQure by 14.6% during the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 8,642 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares in the last quarter. Marshall Wace LLP purchased a new stake in uniQure in the 2nd quarter valued at $175,000. Cubist Systematic Strategies LLC lifted its stake in uniQure by 130.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 14,454 shares in the last quarter. Finally, Algert Global LLC purchased a new position in uniQure during the 2nd quarter worth $176,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.